Bharat Biotech has received approval from the Drugs Controller General of India (DCGI), to conduct Phase 3 trials of its intranasal SARS-CoV-2 vaccine, BBVI54. The trials will evaluate BBV154 nasal vaccine for both the two-dose primary schedule and booster dose schedule, the company said in a statement.

It further added, that Intranasal vaccines are easier to administer in mass immunisation campaigns and help reduce or stop transmission.

The trials for the same will be conducted at nine different sites in the country.

On Thursday the DCGI granted conditional market approval for Covishield and Covaxin.

Last week, the Subject Expert Committee (SEC), of the Central Drugs Standard Control Organisation(CDSCO), in India had recommended that Covishield and Covaxin vaccines be granted regular market approval but with certain conditions, the CDSCO had tweeted.